ESMO 2019 | SB8: a bevacizumab biosimilar for NSCLC

Martin Reck

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses a Phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous Non-Small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video